menu
    • menu
    [{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Treeway","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Edaravone","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Ferrer Internacional \/ Treeway","highestDevelopmentStatusID":"10","companyTruncated":"Ferrer Internacional \/ Treeway"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"CNIC","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Aspirin","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ferrer Internacional \/ CNIC","highestDevelopmentStatusID":"12","companyTruncated":"Ferrer Internacional \/ CNIC"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Edaravone","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Ferrer Internacional \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ferrer Internacional \/ Not Applicable"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Asceneuron","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"ASN90","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Ferrer Internacional \/ Ferrer Internacional","highestDevelopmentStatusID":"6","companyTruncated":"Ferrer Internacional \/ Ferrer Internacional"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"United Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Treprostinil Sodium","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"Ferrer Internacional \/ Ferrer Internacional","highestDevelopmentStatusID":"12","companyTruncated":"Ferrer Internacional \/ Ferrer Internacional"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Verge Genomics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"VRG50635","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Ferrer Internacional \/ Ferrer Internacional","highestDevelopmentStatusID":"6","companyTruncated":"Ferrer Internacional \/ Ferrer Internacional"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Edaravone","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ferrer Internacional \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ferrer Internacional \/ Not Applicable"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Edaravone","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ferrer Internacional \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ferrer Internacional \/ Not Applicable"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"FNP-223","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ferrer Internacional \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ferrer Internacional \/ Not Applicable"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"United Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Treprostinil Sodium","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ferrer Internacional \/ Ferrer Internacional","highestDevelopmentStatusID":"14","companyTruncated":"Ferrer Internacional \/ Ferrer Internacional"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"FNP-223","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ferrer Internacional \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ferrer Internacional \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Ferrer Internacional

    Menu

    Ferrer Internacional

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ferrer Internacional

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Ferrer Internacional

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FNP-223

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ferrer Advances Research on Progressive Supranuclear Palsy with Phase II

                            Details : FNP-223 is a small molecule oral tablet, which is being evaluated in the mid-stage clinical trial studies to slow the progression of Progressive Supranuclear Palsy.

                            Brand Name : FNP-223

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 17, 2024

                            Lead Product(s) : FNP-223

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ferrer Internacional

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Ferrer Internacional

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FNP-223

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ferrer Advances Research into PSP with the Inclusion of the First Participant in a Trial

                            Details : FNP-223 is an orally administered small molecule drug candidate, which is currently being evaluated for the treatment of progressive supranuclear palsy.

                            Brand Name : FNP-223

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 12, 2024

                            Lead Product(s) : FNP-223

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ferrer Internacional

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Ferrer Internacional

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Treprostinil Sodium

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Approved

                            Recipient : United Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Ferrer Obtains the Distribution Rights of a Potential Treatment for IPF and PPF

                            Details : The agreement aims for the distribution of Tyvaso (treprostinil inhalation solution), a drug-device combination authorized for the treatment of WHO Group 3 PH-ILD.

                            Brand Name : Tyvaso

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 27, 2024

                            Lead Product(s) : Treprostinil Sodium

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Approved

                            Recipient : United Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Ferrer Internacional

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Ferrer Internacional

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VRG50635

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Recipient : Verge Genomics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Verge Genomics Partners with Ferrer To Co-Develop ALS Therapy VRG50635

                            Details : The collaboration aims to co-develop VRG50635, Verge’s potent PIKfyve inhibitor, for treating sporadic & familial amyotrophic lateral sclerosis in various regions, including Europe & Southeast Asia.

                            Brand Name : VRG50635

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 25, 2024

                            Lead Product(s) : VRG50635

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Recipient : Verge Genomics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Ferrer Internacional

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Ferrer Internacional

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Edaravone

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ferrer Reports Top-Line Results from Phase III ADORE Study in ALS

                            Details : FAB122 (edaravone) is an investigational once daily, oral, small molecule drug candidate, which is currently being evaluated for the treatment of amyotrophic lateral sclerosis.

                            Brand Name : FNP 122

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 10, 2024

                            Lead Product(s) : Edaravone

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Ferrer Internacional

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Ferrer Internacional

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Edaravone

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ferrer Extends their Clinical Study in Amyotrophic Lateral Sclerosis (ALS)

                            Details : FAB122 (edaravone) is an investigational once daily, oral, small molecule drug candidate, which is currently being evaluated for the treatment of amyotrophic lateral sclerosis.

                            Brand Name : FNP 122

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 22, 2023

                            Lead Product(s) : Edaravone

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Ferrer Internacional

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Ferrer Internacional

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ASN90

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Recipient : Asceneuron

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Ferrer Acquires Worldwide Rights to ASN90, an O-GlcNAcase Inhibitor From Asceneuron, Exclusively to Treat Prog...

                            Details : Under the licensing agreement, Ferrer obtains the exclusive worldwide rights to develop and commercialize ASN90, an O-GlcNAcase inhibitor, in progressive supranuclear palsy (PSP), an orphan, tau-related disease with a high unmet medical need.

                            Brand Name : ASN90

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 22, 2023

                            Lead Product(s) : ASN90

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Recipient : Asceneuron

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Ferrer Internacional

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Ferrer Internacional

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aspirin,Ramipril,Simvastatin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Sponsor : CNIC

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            The Polypill Reduces Cardiovascular Mortality By 33% In Patients Treated After Myocardial Infarction

                            Details : The polypill includes three drugs (aspirin, an ACE inhibitor, and a statin), is effective at preventing secondary adverse cardiovascular events in people who have previously had a heart attack.

                            Brand Name : Polypill

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 26, 2022

                            Lead Product(s) : Aspirin,Ramipril,Simvastatin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Sponsor : CNIC

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Ferrer Internacional

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Ferrer Internacional

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Treprostinil Sodium

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Recipient : United Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Ferrer Announces Distribution Agreement with United Therapeutics for Treprostinil Inhalation Solution for Pulm...

                            Details : Under the agreement, Ferrer has been appointed as the exclusive, worldwide distributor to commercialise Tyvaso (treprostinil) for the treatment of PH-ILD, a rare, serious and progressive disease without an approved treatment in Europe and many other part...

                            Brand Name : Tyvaso

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 28, 2022

                            Lead Product(s) : Treprostinil Sodium

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Recipient : United Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Ferrer Internacional

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Ferrer Internacional

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Edaravone

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            First Patient Enrolled In Ferrer's FNP122 ADORE Phase III Clinical Trial For Amyotrophic Lateral Sclerosis (AL...

                            Details : FNP122 as an oral formulation of edaravone in ALS patients. Edaravone is an antioxidant and free radical scavenger that has been shown to reduce excess oxidative stress and cell death1, playing an important role in the pathology of ALS.

                            Brand Name : FNP122

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 09, 2021

                            Lead Product(s) : Edaravone

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth